Domov › Sklerodermia › Illinois
Klinické štúdie Sklerodermia v štáte Illinois
11 štúdií pre Sklerodermia hľadá účastníkov v zariadeniach v štáte Illinois.
Mestá v štáte Illinois
Oficiálny text štúdie (anglicky)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Prebieha náborFáza 1
Vek 18 až 74 · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Prebieha náborFáza 1
Vek 18 až 70 · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Prebieha náborFáza 2/3
Vek 18 až 75 · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
Prebieha náborFáza 1/2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 31. 7. 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
Prebieha náborFáza 1
Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 7. 2026 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 5. 2025 · NCT05892614Z ClinicalTrials.gov, dáta načítané 4. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.